Molecularly targeted therapies for thyroid cancers

Endocrine Practice

Volumn 15, Issue 6, 2009, Pages 605-611

  Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LEVOTHYROXINE; MOTESANIB; PLACEBO; PLX 4032; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; SCATTER FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; XL 184; XL 281; ANTINEOPLASTIC AGENT; NEW DRUG; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANAPLASTIC CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIFFERENTIATED THYROID CARCINOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MEDLINE; METASTASIS; MOLECULAR THERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ONCOCYTOMA; ONCOGENE; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRECANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; PUBLICATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SYSTEMATIC REVIEW; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE; ANIMAL; DRUG DESIGN; THYROID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 75549086941     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09131.RAR     Document Type: Review

References (62)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Bethesda, Maryland: http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Accessed for verification June 1, 2009.
3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-791.
4. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.
5. Cooper DS, Doherty GM, Haugen BR, et al (American Thyroid Association Guidelines Taskforce). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
6. Maloof F, Vickery AL, Rapp B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131. J Clin Endocrinol Metab. 1956;16:1-27.
7. Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma: a 40 years' experience. Q J Nucl Med Mol Imaging. 2004;48:12-19.
8. Jiménez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008;37:481-496, x-xi.
9. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999;16:34-41.
10. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797-1808.
11. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8:83-95.
12. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077-3080.
13. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol. 2008;5:521-530.
14. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res. 2008;14:3651-3656.
15. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:656-658.
16. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129:552-558.
17. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667-3670.
18. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 2009;21:296-303.
19. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol. 2008;5:102-111.
20. Santarpia L, Ye L, Gagel RF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med. 2009;266:99-113.
21. Schwartz GK, Yazji S, Mendelson DS, et al. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients with advanced solid tumors. Presented at: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; October 21-24, 2008; Geneva, Switzerland.
22. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Presented at: 45th American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2009; Orlando, Florida.
23. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66:8715-8721.
24. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52.
25. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
26. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91:4070-4076.
27. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole- 3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116-1119.
28. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645-4655.
29. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284-7290.
30. Cui JJ. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat. 2007;17:1035-1045.
31. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:2369-2376.
32. Sherman SI, Wirth LJ, Droz JP, et al (Motesanib Thyroid Cancer Study Group). Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31-42.
33. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-3801.
34. Pacini F, Sherman SI, Schlumberger M, et al. Exacerbation of postsurgical hypothyroidism during treatment of advanced differentiated (DTC) or medullary (MTC) thyroid carcinoma with AMG 706. Horm Res. 2007;68(suppl 3):29.
35. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426-437.
36. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
37. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
38. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
39. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol. 2007;19:18-23.
40. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol. 2007;25(18)(suppl):14065.
41. National Comprehensive Cancer Network. Clinical practice guidelines for thyroid carcinoma, version 2009a. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp. Accessed for verification September 4, 2009.
42. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009;19:407-412.
43. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): the M. D. Anderson Cancer Center (MDACC) experience. Presented at: 45th American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2009; Orlando, Florida.
44. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-23.
45. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med. 2008;148:567.
46. Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008;19:547-552.
47. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer [abstract]. J Clin Oncol. 2008;26(15)(suppl):6025.
48. Ravaud A, de la Fouchardière C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial [abstract]. J Clin Oncol. 2008;26(15)(suppl):6058. http://www.asco.org/ ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst-detail- view&confID=55&abstractID=33144. Accessed for verification June 1, 2009.
49. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23:5474-5483.
50. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-4713.
51. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16:239-249.
52. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23:6056-6063.
53. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16:1391-1397.
54. Wells SA Jr. Molecular targeted therapeutics in medullary thyroid carcinoma: results of recent clinical trials. In: Frontiers in Thyroid Cancer: American Thyroid Association Guidelines in Clinical Practice. Proceedings of the American Thyroid Association National Thyroid Cancer Workshop II; January 23-24, 2009; Miami, Florida.
55. Akeno-Stuart N, Croyle M, Knauf JA, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007;67:6956-6964.
56. Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG, Robinson B. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer [abstract]. J Clin Oncol. 2008;26(May 20 suppl):6024.
57. Mineo R, Costantino A, Frasca F, et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology. 2004;145:4355-4365.
58. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol. 2005;29:544-549.
59. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000;11:19-30.
60. Kurzrock R, Sherman S, Hong D, et al. A phase 1 study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC). Presented at: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; October 21-24, 2008; Geneva, Switzerland.
61. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
62. Chintala L, Kurzrock R, Fu S, et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156) [abstract]. J Clin Oncol. 2008;26(15)(suppl):3593.